There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?

There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?

There is a lot of uncertainty about the use of liquid biopsies (ctDNA). Can you identify situations where analysis of ctDNA may be complementary to NGS-based assessment of tissue samples?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Clermont-Ferrand, France